Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Novartis wins USFDA breakthrough tag for Capmatinib to treat lung cancer

      Novartis wins USFDA breakthrough tag for Capmatinib to treat lung cancer

      Medical Dialogues Bureau8 Sept 2019 9:25 AM IST
      Novartis is aiming to win approval for oral capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small...
      Bristol-Myers blockbuster Opdivo fails to meet goal of brain tumour study

      Bristol-Myers blockbuster Opdivo fails to meet goal of brain tumour study

      Medical Dialogues Bureau8 Sept 2019 9:15 AM IST
      The drug, Opdivo, when used along with the current standard of care for glioblastoma multiforme, did not prevent cancer from spreading when compared...
      Cigna new plan to cover expensive gene therapies including Novartis Zolgensma, Luxturna

      Cigna new plan to cover expensive gene therapies including Novartis Zolgensma, Luxturna

      Medical Dialogues Bureau8 Sept 2019 9:00 AM IST
      The first two gene therapies to be included in Cigna Corp's program are blindness therapy, Luxturna, and the most expensive drug in the world...
      Lupin gets USFDA nod for generic version of Emend Injection to prevent vomiting associated with chemotherapy

      Lupin gets USFDA nod for generic version of Emend Injection to prevent vomiting associated with chemotherapy

      Medical Dialogues Bureau7 Sept 2019 9:45 AM IST
      Fosaprepitant for injection is a generic version of Merck Sharp & Dohme Corp's Emend for injection in the same strength, Lupin said.New Delhi:...
      Cipla, B J Wadia Hospital enter partnership to set up paediatric palliative care unit

      Cipla, B J Wadia Hospital enter partnership to set up paediatric palliative care unit

      Medical Dialogues Bureau7 Sept 2019 9:40 AM IST
      Cipla Foundation strongly believes that palliative care focuses on providing relief from symptoms and stress of illness at any point, yet most...
      Sterling Biotech: NCLAT says payments to settle dues to be certified as clean money by ED

      Sterling Biotech: NCLAT says payments to settle dues to be certified as clean money by ED

      Medical Dialogues Bureau7 Sept 2019 9:30 AM IST
      The NCLAT further said to Sterling Biotech counsel: "You will have to get the verification done as to whether the money is genuine nor not".New Delhi:...
      Roche touts drugs pipeline, rules out Merger and Acquisition just to boost sales

      Roche touts drugs pipeline, rules out Merger and Acquisition just to boost sales

      Medical Dialogues Bureau7 Sept 2019 9:15 AM IST
      Roche has twice upgraded 2019 sales forecasts, the latest time to mid- to high-single-digit percentage rate growth, as medicines including Ocrevus for...
      Sumitomo Dainippon Pharma to acquire 10pc stake in Roivant Sciences for USD 3 billion

      Sumitomo Dainippon Pharma to acquire 10pc stake in Roivant Sciences for USD 3 billion

      Medical Dialogues Bureau7 Sept 2019 9:00 AM IST
      The deal, which will open up new drug lines for Sumitomo Dainippon, will also give it the option to acquire interests in an additional six businesses,...
      ENDS devices inlcuding e-Cigarettes, E-Sheesha classified as DRUGS, under DCA, Holds CDSCO DTAB

      ENDS devices inlcuding e-Cigarettes, E-Sheesha classified as DRUGS, under DCA, Holds CDSCO DTAB

      Medical Dialogues Bureau6 Sept 2019 5:16 PM IST
      New Delhi: Clearly stating that E-Sheesha, E-Nicotine, Flavoured Hookah and the like devices are recognized as "Drugs" under Section 26A of the Drugs...
      Laurus Labs gets USFDA Establishment Inspection Report for Visakhapatnam units

      Laurus Labs gets USFDA Establishment Inspection Report for Visakhapatnam units

      Medical Dialogues Bureau6 Sept 2019 1:03 PM IST
      The establishment inspection report (EIR) from US Food and Drug Administration (USFDA) is for company's active pharmaceutical ingredients units 1 and...
      SEBI directs Sun Pharma to undergo forensic audit of financial statements for FY16-18

      SEBI directs Sun Pharma to undergo forensic audit of financial statements for FY16-18

      Medical Dialogues Bureau6 Sept 2019 9:50 AM IST
      Sun Pharma, however, did not provide any specific details on the reasons for the Securities and Exchange Board of India to order the forensic...
      Unichem Labs successfully completes USFDA inspection of Pithampur facility

      Unichem Labs successfully completes USFDA inspection of Pithampur facility

      Medical Dialogues Bureau6 Sept 2019 9:45 AM IST
      "The United States Food and Drug Administration (USFDA) conducted an inspection at the Company's Pithampur, Active Pharmaceutical Ingredients (APIs)...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok